Biological Information

Background Information:

Serine/threonine protein kinases RSKs contain three isoforms RSK1, RSK2 and RSK3 and act at the distal end of MAPK Signaling pathway. They are directly phosphorylated and activated by ERK1/2 in response to many growth factors, peptide hormones and neurotransmitters. RSKs have been shown to regulate apoptosis through phosphorylation and inactivation of the pro-apoptotic protein BAD, and cell cycle since the kinase Myt1 is a RSK target. RSK3 (Ribosomal protein S6 kinase 3, SK6-alpha, MAPKAPK1C) is especially interesting, because it features an additional nuclear targeting signal near its N-terminus, and can phosphorylate a variety of transcription factors (CREB, TCF/Lef, Myc, the estrogen receptor, and the Fos subunit of AP-1). GenBank XM_004469

Target Class:

Kinase

Family:

AGC

Sub Family:

Protein Ser/Thr

Protein Name:

RSK3

Protein Aliases:

90 kDa ribosomal protein S6 kinase 2|p90-RSK 2|p90RSK2|MAP kinase-activated protein kinase 1c|MAPK-activated protein kinase 1c|MAPKAP kinase 1c|MAPKAPK-1c|Ribosomal S6 kinase 3|RSK-3|pp90RSK3

Accession Number:

NM_001006932.1; NM_021135.4

UniProt Number:

Q15349

Gene Name:

RPS6KA2

Gene ID:

6196

Gene Aliases:

RSK|RSK3|HU-2|MAPKAPK1C

Target Species:

Human

Usage

Product Type:

Enzymes

Application:

Drug Discovery & Development

Storage Conditions:

1 year at -70°C

Usage disclaimer:

These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Assay Information

Assay Type:

Enzymatic

Bioassay Data

Trademark Statement:

For Research Use Only

Clinical Relevance

Therapeutic Area:

Oncology/Immuno-Oncology